Spermatogenic Failure 3 (SPGF3) Cell Models for Research

Spermatogenic Failure 3 (SPGF3) is a rare genetic disorder characterized by severe spermatogenic failure, leading to male infertility. The exact prevalence is unknown, but it is estimated to affect a small fraction of infertile men. According to the World Health Organization (WHO), infertility affects approximately 15% of couples worldwide, with male factors contributing to about 50% of cases. SPGF3 is caused by mutations in the SYCP3 gene, which plays a critical role in meiotic recombination and chromosome synapsis. The condition is inherited in an autosomal recessive manner. Clinical presentation includes azoospermia or severe oligozoospermia, with no other systemic manifestations. Diagnosis is based on semen analysis and genetic testing. Currently, there is no cure, and assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI) are the only option for affected individuals, but success rates are low. The National Cancer Institute (NCI) does not track this condition as it is not a cancer, but the genetic basis is well-documented in the NCBI Gene database.

SPGF3 serves as an excellent model for studying meiosis, spermatogenesis, and the molecular mechanisms underlying male infertility. The SYCP3 gene encodes a component of the synaptonemal complex, which is essential for proper chromosome pairing and recombination during meiosis. Mutations in SYCP3 disrupt these processes, leading to meiotic arrest and germ cell apoptosis. Research on SPGF3 can provide insights into the fundamental biology of meiosis, which is relevant not only to infertility but also to aneuploidy and miscarriage. Public datasets, such as those in the Gene Expression Omnibus (GEO), contain transcriptomic data from patient-derived samples and animal models, enabling researchers to investigate gene expression changes and identify potential therapeutic targets. Open questions include the precise molecular pathways downstream of SYCP3 dysfunction and the potential for gene therapy or pharmacological interventions to restore fertility.

SPGF3 is not a cancer, but the molecular pathways involved in its pathogenesis are critical for meiosis. The key pathways include:

• • Meiotic Recombination Pathway: SYCP3 is a structural component of the synaptonemal complex, which facilitates homologous chromosome pairing and recombination. Mutations disrupt this process, leading to meiotic arrest.
• • DNA Damage Response Pathway: Defects in SYCP3 can trigger the DNA damage checkpoint, resulting in apoptosis of spermatocytes. This involves activation of ATM/ATR kinases and downstream effectors such as p53.
• • Apoptosis Pathway: In response to meiotic failure, spermatocytes undergo apoptosis via the intrinsic pathway, involving BAX/BCL-2 family proteins and caspases.

Data from ClinVar and COSMIC (for germline mutations).

The primary deregulated network is the meiotic recombination machinery. Key nodes include:

• • SYCP3: Central component of the synaptonemal complex.
• • SYCP1, SYCP2: Other components of the synaptonemal complex.
• • RAD51, DMC1: Recombinases involved in homologous recombination.
• • MLH1, MSH4: Mismatch repair proteins involved in crossover resolution.
• • ATM/ATR: DNA damage response kinases that monitor meiotic progression.

Additionally, the apoptotic pathway is activated downstream, involving p53, BAX, and caspases.

Organoids derived from testicular tissue can recapitulate spermatogenesis in vitro, providing a platform for studying meiosis and testing drugs. However, they are not widely available for SPGF3 specifically.

• • Knockout Mouse Model: Sycp3 knockout mice are infertile, exhibiting meiotic arrest and apoptosis. This is the most commonly used model.
• • Knock-in Mouse Model: Mice carrying specific patient mutations (e.g., p.R98W) have been generated to study the effect of missense mutations.
• • Chemical-Induced Models: Not commonly used for SPGF3, but busulfan treatment can induce spermatogenic failure in mice.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific SYCP3 mutations. For example, a SYCP3 knockout in a human testicular cell line (e.g., NT2/D1) can be generated to study the loss of function. Alternatively, a knock-in of a patient-specific mutation (e.g., p.R98W) can be introduced to model the disease. These gene-edited cell models are commercially available from various sources and are sequence-verified to ensure accuracy. They provide a valuable tool for functional genomics, drug screening, and mechanistic studies. Using isogenic pairs (wild-type vs. mutant) allows for direct comparison of phenotypic effects without confounding genetic background.

Gene-edited cell lines with SYCP3 mutations can be used to validate the function of SYCP3 in meiosis. For example, knockout lines can be used to study the effects on gene expression, cell cycle progression, and apoptosis. Knock-in lines can be used to assess the impact of specific mutations on protein localization and interaction with other synaptonemal complex components. These models are essential for confirming the pathogenicity of novel variants identified in patients.

Isogenic cell lines can be used in high-throughput screens to identify compounds that rescue meiotic defects or reduce apoptosis. For instance, a screen for small molecules that promote homologous recombination could be performed using a SYCP3 knockout line. Additionally, these models can be used to test the efficacy of potential therapeutic agents, such as antioxidants or hormones, in improving spermatogenesis.

CRISPR-based synthetic lethality screens can identify genes that are essential for survival in SYCP3-mutant cells but not in wild-type cells. These synthetic lethal partners could serve as potential drug targets for treating infertility or as biomarkers for diagnosis. For example, inhibiting a gene that is synthetic lethal with SYCP3 loss might selectively kill mutant spermatocytes, potentially offering a therapeutic strategy.